Perinatal Opioid Use

MUSC Women's Reproductive Behavioral Health Program for Opioid Use During Pregnancy

To compare maternal and newborn outcomes among pregnant women with OUD receiving care via telemedicine versus in-person.

Participants: Pregnant women with OUD.

Intervention: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine.

Design: A cohort derived from a prospectively collected database including 98 women receiving perinatal OUD treatment in an obstetric practice by telemedicine or in-person and followed until 6-8 weeks postpartum from September, 2017 to December, 2018. Logistic regression with propensity score adjustment was applied to reduce group selection bias and control for potentially confounding variables.

Setting: Four outpatient obstetric practices in the southeast.

Inclusion Criteria:

• Adult females, any race or ethnicity, age 18-45 years
• Currently pregnant
• Opioid Use Disorder (OUD)
• received in person or telemedicine treatment for OUD in their obstetrician's office

Exclusion Criteria:

• Not currently pregnant or receiving perinatal care
• Not in agreement with Patient-Physician Agreement